ACOR Acorda Therapeutics Inc.

25.80
+0.70  (3%)
Previous Close 25.10
Open 26.05
Price To book 1.77
Market Cap 1206076883
Shares 46,747,166
Volume 640,076
Short Ratio 6.21
Av. Daily Volume 662,559

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Ampyra
Improve walking in patients with multiple sclerosis
Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
CVT-427
Migraine
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. However, company noted November 20, 2017 that program will be discontinued.
Tozadenant
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Dalfampridine
Post stroke deficits
Phase 3 data released February 9, 2017 - primary endpoint met. NDA filing announced June 29, 2017. However, FDA issued a Refuse-To-File letter August 30, 2017. NDA December 2017.
INBRIJA (CVT-301)
OFF episodes of Parkinson’s disease (PD)

Latest News

  1. Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
  2. Acorda Therapeutics Inc (NASDAQ:ACOR): Does -148.17% Earnings Drop In A Year Reflect The Long-Term Trend?
  3. Acorda reports 4Q loss
  4. Acorda Therapeutics, Inc. to Host Earnings Call
  5. Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
  6. Acorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
  7. Options Traders Expect Huge Moves in Acorda Therapeutics (ACOR) Stock
  8. Acorda Fourth Quarter/Year End 2017 Update
  9. Analysis: Positioning to Benefit within Alliqua BioMedical, Donegal Group, QAD, ManpowerGroup, Acorda Therapeutics, and Arena Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  10. See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
  11. Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8%
  12. Today’s Research Reports on Trending Tickers: Acorda Therapeutics and BioCryst Pharmaceuticals
  13. Blog Exposure - Acorda Therapeutics’ Stock Surges Amidst Rumors Of Takeover
  14. This Biotech Stock Rocketed 15% On Rumors Biogen Could Buy It
  15. Here's Why Acorda Therapeutics Inc. Stock Is Surging Today
  16. Benzinga Pro's 6 Stocks To Watch Today
  17. Stocks making the biggest moves premarket: IBM, AXP, ACOR, LOW, FL, NKE & more
  18. The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Acorda Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of January 17, 2018
  19. FINAL SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) and Lead Plaintiff Deadline: January 17, 2018
  20. Kessler Topaz Meltzer & Check, LLP - SHAREHOLDER REMINDER:  Deadline in Class Action Lawsuit Filed Against Acorda Therapeutics, Inc. – ACOR